Eli Lilly and Co.’s latest phase III results for the obesity and overweight populations suggest its triple agonist, retatrutide, can deliver significant weight loss that, in turn, leads to reduced osteoarthritis knee pain.
The opioid crisis may not be front and center anymore, but it’s raging still. A major problem is that overdose-reversal drugs don’t last long enough to help users who opt out of hospital treatment after they are revived. Elysium Therapeutics Inc. CEO Greg Sturmer talks with Randy Osborne about his firm’s candidate for a solution to the medical and societal problem.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Askbio, Biogen, Opus, OS Therapies, Roche, Senti, Teva, Tris.
Biopharma happenings, including deals and partnerships, and other news in brief: Adverum, Akero, Eli Lilly, Formycon, Probiogen, Novo Nordisk, Spica, Zydus.
D3 Bio Inc. secured $108 million in a series B financing round Dec. 9 to support its planned phase III program of lead oral KRAS G12C inhibitor, elisrasib (D3S-001).
RSS
